GEN Exclusives

More »

GEN News Highlights

Back to Item »

Novartis’ Canakinumab Succeeds in First Phase III Study in Systemic Juvenile Idiopathic Arthritis

Data showed IL-1β-targeting mAb led to up to 100% improvement in symptoms.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?